Funder
Beijing Xisike Clinical Oncology Research Foundation
Jiangsu Commission of Health
Publisher
Springer Science and Business Media LLC
Reference61 articles.
1. Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7–30.
2. Chai, Y., Chen, Y., Zhang, D., Wei, Y., Li, Z., Li, Q., & Xu, B. (2022). Homologous recombination deficiency (HRD) and BRCA 1/2 gene mutation for predicting the effect of platinum-based neoadjuvant chemotherapy of early-stage triple-negative breast cancer (TNBC): A systematic review and meta-analysis. Journal of Personalized Medicine, 12, 323.
3. Lavoro, A., Scalisi, A., Candido, S., Zanghi, G. N., Rizzo, R., Gattuso, G., Caruso, G., Libra, M., & Falzone, L. (2022). Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families? International Journal of Oncology. https://doi.org/10.3892/ijo.2022.5349
4. Ngoi, N., & Tan, D. (2021). The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: Do we need it? ESMO Open, 6, 100144.
5. Lheureux, S., Braunstein, M., & Oza, A. M. (2019). Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA: A Cancer Journal for Clinicians, 69, 280–304.